These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 32777582)
21. Resolution of secondary hemophagocytic lymphohistiocytosis after treatment with the JAK1/2 inhibitor ruxolitinib. Goldsmith SR; Saif Ur Rehman S; Shirai CL; Vij K; DiPersio JF Blood Adv; 2019 Dec; 3(23):4131-4135. PubMed ID: 31821455 [TBL] [Abstract][Full Text] [Related]
22. A case of hemophagocytic lymphohistiocytosis with a significant response to baricitinib: a first report with review of literature. Irino K; Jinnouchi F; Nakano S; Sawabe T Clin Rheumatol; 2023 Jul; 42(7):1959-1963. PubMed ID: 36947281 [TBL] [Abstract][Full Text] [Related]
23. Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial. Ahmed A; Merrill SA; Alsawah F; Bockenstedt P; Campagnaro E; Devata S; Gitlin SD; Kaminski M; Cusick A; Phillips T; Sood S; Talpaz M; Quiery A; Boonstra PS; Wilcox RA Lancet Haematol; 2019 Dec; 6(12):e630-e637. PubMed ID: 31537486 [TBL] [Abstract][Full Text] [Related]
24. [Hemophagocytic lymphohistiocytosis associated with Plasmodium falciparum]. Harioly Nirina MOM; Raheritiana TM; Harioly Nirina MOJ; Rasolonjatovo AS; Rakoto Alson AO; Rasamindrakotroka A Med Mal Infect; 2017 Dec; 47(8):569-570. PubMed ID: 28844807 [No Abstract] [Full Text] [Related]
25. Hemophagocytic lymphohistiocytosis secondary to Falciparum malaria in a 5 year-old boy. Santos JA; Neves JF; Venâncio P; Gouveia C; Varandas L Ann Hematol; 2015 Jan; 94(1):161-3. PubMed ID: 24880248 [No Abstract] [Full Text] [Related]
26. JAK inhibition for murine HLH requires complete blockade of IFN-γ signaling and is limited by toxicity of JAK2 inhibition. Chaturvedi V; Lakes N; Tran M; Castillo N; Jordan MB Blood; 2021 Sep; 138(12):1034-1039. PubMed ID: 34232994 [TBL] [Abstract][Full Text] [Related]
27. Ruxolitinib is an alternative to etoposide for patient with hemophagocytic lymphohistiocytosis complicated by acute renal injury: A case report. Yan WL; Yang SL; Zhao FY; Xu XJ J Oncol Pharm Pract; 2022 Jan; 28(1):222-227. PubMed ID: 34074166 [TBL] [Abstract][Full Text] [Related]
28. Varied presentation of complicated falciparum malaria in a family. Sanklecha M; Mehta N; Bagban H Indian Pediatr; 2012 May; 49(5):413-4. PubMed ID: 22700669 [TBL] [Abstract][Full Text] [Related]
29. Janus Family kinase (JAK) inhibitors in HLH and severe COVID-19. Wilcox RA Am J Hematol; 2020 Dec; 95(12):1448-1451. PubMed ID: 32918336 [No Abstract] [Full Text] [Related]
31. Ruxolitinib as first-line treatment in secondary hemophagocytic lymphohistiocytosis: A single patient experience. Slostad J; Hoversten P; Haddox CL; Cisak K; Paludo J; Tefferi A Am J Hematol; 2018 Feb; 93(2):E47-E49. PubMed ID: 29134683 [No Abstract] [Full Text] [Related]
32. Ruxolitinib treatment permits lower cumulative glucocorticoid dosing in children with secondary hemophagocytic lymphohistiocytosis. Chi Y; Liu R; Zhou ZX; Shi XD; Ding YC; Li JG Pediatr Rheumatol Online J; 2021 Apr; 19(1):49. PubMed ID: 33794928 [TBL] [Abstract][Full Text] [Related]
33. A pilot study of ruxolitinib as a front-line therapy for 12 children with secondary hemophagocytic lymphohistiocytosis. Zhang Q; Wei A; Ma HH; Zhang L; Lian HY; Wang D; Zhao YZ; Cui L; Li WJ; Yang Y; Wang TY; Li ZG; Zhang R Haematologica; 2021 Jul; 106(7):1892-1901. PubMed ID: 32732367 [TBL] [Abstract][Full Text] [Related]
34. Severe Plasmodium vivax cerebral malaria complicated by hemophagocytic lymphohistiocytosis treated with artesunate and doxycycline. Amireh S; Shaaban H; Guron G Hematol Oncol Stem Cell Ther; 2018 Mar; 11(1):34-37. PubMed ID: 27514010 [TBL] [Abstract][Full Text] [Related]
35. Successful treatment of hemophagocytic lymphohistiocytosis in a patient with systemic lupus erythematosus with ruxolitinib: a case report. Jung JI; Kim JY; Kim MH; Park JK; Lee EY; Lee EB; Park JW J Rheum Dis; 2024 Apr; 31(2):125-129. PubMed ID: 38559795 [TBL] [Abstract][Full Text] [Related]
36. Cellular and transcriptional impacts of Janus kinase and/or IFN-gamma inhibition in a mouse model of primary hemophagocytic lymphohistiocytosis. Albeituni S; Oak N; Tillman HS; Stroh A; Keenan C; Bloom M; Nichols KE Front Immunol; 2023; 14():1137037. PubMed ID: 37228616 [TBL] [Abstract][Full Text] [Related]
37. Therapeutic efficacy of suppressing the Jak/STAT pathway in multiple models of experimental autoimmune encephalomyelitis. Liu Y; Holdbrooks AT; De Sarno P; Rowse AL; Yanagisawa LL; McFarland BC; Harrington LE; Raman C; Sabbaj S; Benveniste EN; Qin H J Immunol; 2014 Jan; 192(1):59-72. PubMed ID: 24323580 [TBL] [Abstract][Full Text] [Related]
39. Plasmodium falciparum infection transmitted by transfusion: A cause of hemophagocytic syndrome after bone marrow tranplantation in a non-endemic country. Ladeb S; Ben Abdejlil N; Fakhfakh N; Lakhal A; Belloumi D; Ben Hamed L; Kallel A; Torjman L; El Fatimi R; Hmida S; Kallel K; Ben Othman T Transpl Infect Dis; 2018 Jun; 20(3):e12887. PubMed ID: 29573075 [TBL] [Abstract][Full Text] [Related]
40. Combined IFN-γ and JAK inhibition to treat hemophagocytic lymphohistiocytosis in mice. Joly JA; Vallée A; Bourdin B; Bourbonnais S; Patey N; Gaboury L; Théorêt Y; Decaluwe H J Allergy Clin Immunol; 2023 Jan; 151(1):247-259.e7. PubMed ID: 35973477 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]